Latest signals

FDA Approves Breakthrough Treatment for Pancreatic Cancer

Filed · 3 publisher pages · upstream origin unresolved

The US Food and Drug Administration (FDA) has approved a treatment for pancreatic cancer that nearly doubled the overall survival time for patients in clinical trials.

The drug, daraxonrasib, sold under the brand name Rasonque and manufactured by Revolution Medicines, appears to be a breakthrough in treating one of the world's deadliest cancers.

A late-stage clinical trial with 500 patients found that those who took the daily pill had an average survival time of 13.2 months, compared to 6.6 months for those on chemotherapy.

The FDA said the drug provided a 'critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer'.

Pages read

  1. bbc — US drug agency approves breakthrough treatment for pancreatic cancer ·
  2. france24 — FDA approves new drug Rasonque to treat advanced pancreatic cancer ·
  3. le-monde — US approves new treatment for pancreatic cancer ·

Publisher breadth and upstream editorial independence are separate measurements. An unresolved origin is not counted as independent reporting.

Upstream origin test

3 publisher pages; upstream origin unresolved 1–3. Registry news_provenance_registry_v1.

  1. bbc: upstream origin unresolved; cluster not certified.
  2. france24: upstream origin unresolved; cluster not certified.
  3. le-monde: upstream origin unresolved; cluster not certified.

Clusters join only on article-declared upstream credit or strong measured full-text reuse. Publisher domains alone never establish independence.

Lightcap